The benefits of the European Commission’s proposed Supplementary Protection Certificate (SPC) manufacturing and export exemption have been stressed at an event staged by the group representing the generic, biosimilar and value-added medicines industries across Europe.
This is perhaps no surprise, given what the sector could gain if the manufacturing waiver was to be introduced.
"An efficient, pro-competitive legal environment that includes the SPC manufacturing waiver will boost investments in our sector"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze